Project Grant R44AG091987
Award Date 8/20/25
Completion Date 8/19/26
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This $495,699 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) on September 20, 2025. The grant supports the development of a drug candidate, PGI-5128, for the treatment of agitation in Alzheimer's disease. The primary objectives are to: 1) Evaluate the efficacy of PGI-5128 in reducing aggressive behaviors in transgenic Alzheimer's disease mouse models, and 2) Initiate investigational new drug (IND)-enabling...
- This Project Grant award of $475,014.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel neurotrophic therapeutic for treating the cognitive deficits associated with Alzheimer's disease. The key products and services to be delivered through this grant include: Scaling up the production of a recombinant, non-erythropoietic neurotrophic protein that has demonstrated cognitive enhancement effects in Alzheimer's disease models. Evaluating the toxicity...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) is funding the development of novel ambroxol analogs as potential disease-modifying therapies for Alzheimer's disease and related dementias. The $496,600 award to Zywie LLC will be used to: 1) scale up manufacturing of two ambroxol analog compounds (ZW-002 and ZW-010) under non-GLP conditions, optimizing synthesis and validating analytical methods; 2) conduct short-term toxicology studies in healthy...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $391,850 to support the development of a RUNX1 modulator therapy to slow cognitive decline in Alzheimer's disease (AD). The primary objectives are to: 1) optimize the safety and potency of a RUNX1-targeting antisense oligonucleotide (ASO) development candidate, and 2) demonstrate the efficacy of the RUNX1 ASO in a mouse model of AD using molecular biomarkers and behavioral endpoints. The goal is...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...